Bremelanotide Injection

Overview of Bremelanotide Injection

Dosage Strength

10 mg/mL 2 mL Vial

General Information

Bremelanotide is an injectable agonist of the melanocortin receptor. It is injected subcutaneously and is approved for the treatment of Hypoactive Sexual Desire Disorder (HSDD), or poor sexual desire, in premenopausal females. It has a distinct method of action that aids in the activation of brain circuits involved in appropriate sexual responses. Safety and efficacy were established in premenopausal females aged 19 to 56 years old with HSDD that causes significant distress or interpersonal difficulty and is NOT due to a co-existing medical or psychiatric condition, relationship problems, or the effects of a medication or other drug substance. Bremelanotide is not approved to treat HSDD in postmenopausal women, men, or to improve sexual performance. In clinical trials, around 25% of patients treated with bremelanotide exhibited an increase of 1.2 or more in their sexual desire score (rated on a scale of 1.2 to 6, with higher values indicating stronger sexual desire), compared to approximately 17% of those taking placebo. Bremelanotide is used “as needed” before to expected sexual activity; women are not required to take the medication on a daily basis. 1

References

1. Vyleesi (bremelanotide) injection package insert. Waltham, MA: AMAG Pharmaceuticals, Inc.; 2020 Oct.

Legal Disclaimer: All information presented in this website is intended for informational purposes only and not for the purpose of rendering medical advice.

Get Started For $99 Initial Provider Consult